Skip to main content
. 2019 Oct 10;9:14551. doi: 10.1038/s41598-019-51211-y

Figure 2.

Figure 2

Response and follow up of imatinib mesylate in patients with locally advanced or recurrent diffuse-type TGCT. NED = No evidence of disease, AWD = Alive with disease.